snbr-20250628

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2025


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-25121

_______________________________________________________________________

SLEEP NUMBER CORPORATION

(Exact name of registrant as specified in its charter)


Minnesota		41-1597886
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)


1001 Third Avenue South
Minneapolis,	Minnesota	55404
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (763) 551-7000

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	SNBR	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted

pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the

registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller

reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller

reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 28, 2025, 22,771,000 shares of the registrant’s Common Stock were outstanding.


1 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited - in thousands, except per share amounts)


	June 28, 2025	December 28, 2024
Assets
Current assets:
Cash and cash equivalents	$1,349	$1,950
Accounts receivable, net of allowances of $1,127 and $1,113, respectively	16,017	17,516
Inventories	99,450	103,152
Prepaid expenses	20,824	14,568
Other current assets	37,885	44,098
Total current assets	175,525	181,284

Non-current assets:
Property and equipment, net	109,105	129,574
Operating lease right-of-use assets	339,149	356,641
Goodwill and intangible assets, net	66,301	66,412
Deferred income taxes	31,803	33,575
Other non-current assets	82,629	93,324
Total assets	$804,512	$860,810

Liabilities and Shareholders’ Deficit
Current liabilities:
Borrowings under revolving credit facility	$563,900	$546,600
Accounts payable	111,212	107,619
Customer prepayments	41,141	46,933
Accrued sales returns	15,650	19,092
Compensation and benefits	20,929	31,038
Taxes and withholding	17,854	18,619
Operating lease liabilities	82,209	82,307
Other current liabilities	50,326	55,804
Total current liabilities	903,221	908,012

Non-current liabilities:
Operating lease liabilities	287,585	307,201
Other non-current liabilities	94,394	97,183
Total liabilities	1,285,200	1,312,396

Shareholders’ deficit:
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding	—	—
Common stock, $0.01 par value; 142,500 shares authorized, 22,771 and 22,388 shares issued and outstanding, respectively	228	224
Additional paid-in capital	31,942	27,390
Accumulated deficit	(512,858)	(479,200)
Total shareholders’ deficit	(480,688)	(451,586)
Total liabilities and shareholders’ deficit	$804,512	$860,810

See accompanying notes to condensed consolidated financial statements.


2 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited - in thousands, except per share amounts)


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Net sales	$327,925	$408,413	$721,186	$878,862
Cost of sales	134,180	166,923	286,906	361,198
Gross profit	193,745	241,490	434,280	517,664

Operating expenses:
Sales and marketing	146,464	182,400	335,567	390,912
General and administrative	29,604	39,573	68,223	78,652
Research and development	9,420	11,578	20,323	24,019
Restructuring costs	8,332	1,819	8,392	12,419
Total operating expenses	193,820	235,370	432,505	506,002
Operating (loss) income	(75)	6,120	1,775	11,662
Interest expense, net	11,734	12,270	22,815	24,569
Loss before income taxes	(11,809)	(6,150)	(21,040)	(12,907)
Income tax expense (benefit)	13,203	(1,099)	12,618	(374)
Net loss	$(25,012)	$(5,051)	$(33,658)	$(12,533)

Basic net loss per share:
Net loss per share – basic	$(1.09)	$(0.22)	$(1.48)	$(0.56)
Weighted-average shares – basic	22,903	22,614	22,804	22,560

Diluted net loss per share:
Net loss per share – diluted	$(1.09)	$(0.22)	$(1.48)	$(0.56)
Weighted-average shares – diluted	22,903	22,614	22,804	22,560

See accompanying notes to condensed consolidated financial statements.


3 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Shareholders’ Deficit

(unaudited - in thousands)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at December 28, 2024	22,388	$224	$27,390	$(479,200)	$(451,586)
Net loss	—	—	—	(8,646)	(8,646)
Stock-based compensation	346	3	3,948	—	3,951
Repurchases of common stock	(74)	—	(563)	—	(563)
Balance at March 29, 2025	22,660	$227	$30,775	$(487,846)	$(456,844)
Net loss	—	—	—	(25,012)	(25,012)
Stock-based compensation	149	1	1,548	—	1,549
Repurchases of common stock	(38)	—	(381)	—	(381)
Balance at June 28, 2025	22,771	$228	$31,942	$(512,858)	$(480,688)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at December 30, 2023	22,235	$222	$16,716	$(458,866)	$(441,928)
Net loss	—	—	—	(7,482)	(7,482)
Stock-based compensation	134	1	4,116	—	4,117
Repurchases of common stock	(43)	—	(570)	—	(570)
Balance at March 30, 2024	22,326	$223	$20,262	$(466,348)	$(445,863)
Net loss	—	—	—	(5,051)	(5,051)
Stock-based compensation	32	1	3,991	—	3,992
Repurchases of common stock	(3)	—	(42)	—	(42)
Balance at June 29, 2024	22,355	$224	$24,211	$(471,399)	$(446,964)

See accompanying notes to condensed consolidated financial statements.


4 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited - in thousands)


	Six Months Ended
	June 28, 2025	June 29, 2024
Cash flows from operating activities:
Net loss	$(33,658)	$(12,533)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	29,096	34,177
Stock-based compensation	5,500	8,109
Net loss on disposals and impairments of assets	775	2,500
Deferred income taxes	1,772	(5,144)
Changes in operating assets and liabilities:
Accounts receivable	1,499	6,587
Inventories	3,702	19,588
Income taxes	2,470	774
Prepaid expenses and other assets	10,381	(1,483)
Accounts payable	8,354	(18,464)
Customer prepayments	(5,792)	(4,625)
Accrued compensation and benefits	(10,086)	7,153
Other taxes and withholding	(3,235)	(1,345)
Other accruals and liabilities	(9,582)	(11,776)
Net cash provided by operating activities	1,196	23,518

Cash flows from investing activities:
Purchases of property and equipment	(8,052)	(14,075)
Payment to secure contractual rights	(3,280)	—
Issuance of note receivable	—	(2,942)
Net cash used in investing activities	(11,332)	(17,017)

Cash flows from financing activities:
Net increase (decrease) in short-term borrowings	12,356	(6,408)
Repurchases of common stock	(944)	(612)
Debt issuance costs	(1,877)	—
Net cash provided by (used in) financing activities	9,535	(7,020)

Net decrease in cash and cash equivalents	(601)	(519)
Cash and cash equivalents, at beginning of period	1,950	2,539
Cash and cash equivalents, at end of period	$1,349	$2,020

See accompanying notes to condensed consolidated financial statements.


5 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Business and Summary of Significant Accounting Policies

Business & Basis of Presentation

The Company prepared the condensed consolidated financial statements as of and for the three and six months ended

June 28, 2025 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company), without

audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in the

opinion of management, all normal recurring adjustments, including the elimination of all significant intra-entity balances

and transactions, necessary to present fairly its financial position as of June 28, 2025 and December 28, 2024, and the

consolidated results of operations and cash flows for the periods presented. The historical and quarterly consolidated

results of operations may not be indicative of the results that may be achieved for the full year or any future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.

Generally Accepted Accounting Principles (GAAP) have been condensed or omitted pursuant to such rules and

regulations. These condensed consolidated financial statements should be read in conjunction with the most recent

audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for

the fiscal year ended December 28, 2024 and other recent filings with the SEC.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to

make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities,

disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the

reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently

an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined

with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected

in the consolidated financial statements in future periods and could be material.

The Company’s critical accounting policies consist of stock-based compensation, warranty liabilities and revenue

recognition.

Accounting Pronouncements Issued But Not Yet Effective

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures"

to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public

companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling

items that meet a quantitative threshold. Additionally, under the amendment, entities are required to disclose the

amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material

individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before

income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations

disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December

15, 2024. The adoption of this standard is not expected to have a material impact on the Company’s consolidated

financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense

Disaggregation Disclosures (Subtopic 220-40)", which requires public business entities to disclose in the notes to the

financial statements more detailed information about the types of expenses included in certain expense captions in the

consolidated financial statements, including purchases of inventory, employee compensation, and depreciation and

amortization. The amendments are effective for the Company beginning with the 2027 annual period and in interim

periods beginning in 2028. Early adoption is permitted. The ASU may be adopted prospectively or retrospectively. The

Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and related

disclosures.

Currently, management does not believe that any other recently issued, but not yet effective accounting

pronouncements, if adopted in their current form, would have a material impact on the Company’s consolidated financial

statements.


6 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

Other Investments

The Company made a payment of $3.3 million during the three months ended June 28, 2025 to secure contractual rights

from a strategic product-development partner. This payment is included in prepaid expenses in the Company’s

condensed consolidated balance sheet and as an investing activity in the Company’s condensed consolidated statement

of cash flows.

2. Fair Value Measurements

At both June 28, 2025 and December 28, 2024, the Company had $19 million of debt and equity securities that fund the

deferred compensation plan and are classified in other non-current assets. The Company also had corresponding

deferred compensation plan liabilities of $19 million at both June 28, 2025 and December 28, 2024 which are included

in other non-current liabilities. The majority of the debt and equity securities are Level 1 as they trade with sufficient

frequency and volume to enable the Company to obtain pricing information on an ongoing basis. Unrealized gains/

(losses) on the debt and equity securities offset those associated with the corresponding deferred compensation plan

liabilities.

3. Inventories

Inventories consisted of the following (in thousands):


	June 28, 2025	December 28, 2024
Raw materials	$6,415	$11,434
Work in progress	168	130
Finished goods	92,867	91,588
	$99,450	$103,152

4. Goodwill and Intangible Assets, Net

Goodwill and Indefinite-lived Intangible Assets

Goodwill was $64.0 million at June 28, 2025 and December 28, 2024. Indefinite-lived trade name/trademarks totaled

$1.4 million at both June 28, 2025 and December 28, 2024.

Definite-lived Intangible Assets

Patents were $2.0 million at both June 28, 2025 and December 28, 2024. Accumulated amortization was $1.1 million at

June 28, 2025 and $1.0 million at December 28, 2024. Amortization expense was $55 thousand for both the three

months ended June 28, 2025 and June 29, 2024, and $0.1 million for both the six months ended June 28, 2025 and

June 29, 2024.

Annual amortization for patents for subsequent years is as follows (in thousands):


2025 (excluding the six months ended June 28, 2025 )		$117
2026		222
2027		222
2028		155
2029		99
2030		45
Total future amortization for definite-lived intangible assets		$860


7 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

5. Credit Agreement

As of June 28, 2025, the Company’s credit facility had a total commitment amount of $673 million. The credit facility, as

amended, is for general corporate purposes and to meet seasonal working capital requirements. The Amended and

Restated Credit and Security Agreement, dated February 14, 2018, among the Company, U.S. Bank National Association

and the several banks and other financial institutions from time to time party thereto (as amended, the Credit

Agreement), includes an accordion feature which allows the Company to increase the amount of the credit facility from

$673 million to $1.0 billion, subject to lenders’ approval. The Credit Agreement provides the lenders with a collateral

security interest in substantially all of the Company’s assets and those of its subsidiaries and requires the Company to

comply with, among other things, a maximum net leverage ratio and a minimum interest coverage ratio.

The Company amended the Credit Agreement on March 3, 2025. The amendment, among other things: (a) adds a

definition for "Liquidity" which means, on any date of determination, the sum of (x) Borrower's and its Subsidiaries'

unrestricted cash that is free and clear of Liens (other than those in favor of the Administrative Agent) plus (y) the

aggregate amount of unused Revolving Credit Commitments available for Credit Events on such date (including the

Borrower's ability to satisfy the requirements of Section 4.1 on such date) (as each is defined in the Credit Agreement);

(b) adds a Liquidity financial covenant wherein the Borrower shall cause the Liquidity to be equal or exceed $40 million

as of the last day of each fiscal month; (c) deems our Net Leverage Ratio as greater than or equal to 4.50 to 1.00 as of

the effective date to set pricing for the Applicable Commitment Fee Rate and Applicable Margin until receipt of the

compliance certificate for the quarterly reporting period ending September 27, 2025, (d) adjusts the permissible

maximum Net Leverage Ratio (as defined in the Credit Agreement) to (I) 4.75 to 1.00 for the quarterly reporting period

ending June 28, 2025, (II) 4.50 to 1.00 for the quarterly reporting period ending September 27, 2025, (III) 4.35 to 1.00 for

the quarterly reporting period ending January 3, 2026, and (IV) 4.00 to 1.00 for each quarterly reporting period occurring

thereafter, and (e) adjusts the permissible minimum Interest Coverage Ratio (as defined in the Credit Agreement) to (I)

1.90 to 1.00 for the quarterly reporting periods ending June 28, 2025 and September 27, 2025, (II) 2.10 to 1.00 for the

quarterly reporting period ending January 3, 2026, and (III) 3.00 to 1.00 for each quarterly reporting period occurring

thereafter. A fee for the amendment was paid to the approving lenders in an amount equal to 20 basis points multiplied

by the sum of such lender's Revolving Credit Commitment and outstanding Term Loans (as each is defined in the Credit

Agreement).

The carrying amount of the outstanding borrowings under the Credit Agreement approximates fair value because

interest rates approximate the current rates available to the Company. Under the terms of the Credit Agreement, the

Company pays a variable rate of interest and a commitment fee based on its leverage ratio. The Credit Agreement

matures in December 2026. The Company was in compliance with all financial covenants as of June 28, 2025.

The following table summarizes the Company’s borrowings under the credit facility ($ in thousands):


	June 28, 2025	December 28, 2024
Outstanding borrowings	$563,900	$546,600
Outstanding letters of credit	$6,847	$7,147
Additional borrowing capacity	$101,753	$123,753
Weighted-average interest rate	7.9%	7.6%

Subsequent to June 28, 2025, the Company’s outstanding letters of credit increased to $9 million.

6. Leases

The Company leases its retail, office and manufacturing space under operating leases which, in addition to the minimum

lease payments, may require payment of a proportionate share of the real estate taxes and certain building operating

expenses. While the Company’s local market development approach generally results in long-term participation in given

markets, the retail store leases generally provide for an initial lease term of five to ten years. The Company’s office and

manufacturing leases provide for an initial lease term of up to fifteen years. In addition, the Company’s mall-based retail

store leases may require payment of variable rent based on net sales in excess of certain thresholds. Certain leases may


8 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

contain options to extend the term of the original lease. The exercise of lease renewal options is at the Company’s sole

discretion. Lease options are included in the lease term only if exercise is reasonably certain at lease commencement.

The Company’s lease agreements do not contain any material residual value guarantees. The Company also leases

vehicles and certain equipment under operating leases with an initial lease term of three to six years.

The Company’s operating lease costs include facility, vehicle and equipment lease costs, but exclude variable lease

costs. Operating lease costs are recognized on a straight-line basis over the lease term, after consideration of rent

escalations and rent holidays. The lease term for purposes of the calculation begins on the earlier of the lease

commencement date or the date the Company takes possession of the property. During lease renewal negotiations that

extend beyond the original lease term, the Company estimates straight-line rent expense based on current market

conditions. Variable lease costs are recorded when it is probable the cost has been incurred and the amount can be

reasonably estimated. Future payments for real estate taxes and certain building operating expenses for which the

Company is obligated are not included in operating lease costs.

At June 28, 2025, the Company’s finance right-of-use assets and lease liabilities were not significant.

Lease costs were as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Operating lease costs(1)	$26,649	$26,909	$53,186	$53,735
Variable lease costs(2)	$37	$8	$140	$(41)

___________________________

(1)Includes short-term lease costs which are not significant.

(2)Variable lease costs include adjustments to percentage rent.

The maturities of operating lease liabilities for subsequent years are as follows(1) (in thousands):


2025 (excluding the six months ended June 28, 2025)	$52,797
2026	99,002
2027	82,575
2028	69,001
2029	48,062
2030	34,064
Thereafter	51,219
Total operating lease payments(2)	436,720
Less: Interest	66,926
Present value of operating lease liabilities	$369,794

___________________________

(1)Total operating lease payments exclude $8 million of legally binding minimum lease payments for leases signed but not yet commenced.

(2)Includes the current portion of $82 million for operating lease liabilities.

Other information related to operating leases was as follows:


	June 28, 2025	December 28, 2024
Weighted-average remaining lease term (in years)	5.2	5.4
Weighted-average discount rate	6.7%	6.6%


9 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


	Six Months Ended
(in thousands)	June 28, 2025	June 29, 2024
Cash paid for amounts included in present value of operating lease liabilities	$53,092	$54,300
Right-of-use assets obtained in exchange for operating lease liabilities	$12,752	$16,313

7. Repurchases of Common Stock

For the three months ended June 28, 2025 and June 29, 2024, we repurchased $0.4 million and $42 thousand,

respectively, of common stock in connection with the vesting of restricted stock grants. For the six months ended

June 28, 2025 and June 29, 2024, we repurchased $0.9 million and $0.6 million, respectively, of common stock in

connection with the vesting of restricted stock grants. We made no purchases under the Board-approved stock purchase

plan in either period. As of June 28, 2025, the remaining authorization under the Board-approved $600 million share

repurchase program was $348 million.

8. Revenue Recognition

Deferred contract assets and deferred contract liabilities are included in the condensed consolidated balance sheets as

follows (in thousands):


	June 28, 2025	December 28, 2024
Deferred contract assets included in:
Other current assets	$28,793	$30,154
Other non-current assets	45,996	48,988
	$74,789	$79,142


	June 28, 2025	December 28, 2024
Deferred contract liabilities included in:
Other current liabilities	$37,008	$38,129
Other non-current liabilities	58,362	60,988
	$95,370	$99,117

Deferred revenue and costs related to SleepIQ® technology are currently recognized on a straight-line basis over the

product's estimated life of 4.5 to 5.0 years because the Company’s inputs are generally expended evenly throughout the

performance period. During the three months ended June 28, 2025 and June 29, 2024, the Company recognized

revenue of $7 million and $10 million, respectively, that was included in the deferred contract liability balances at the

beginning of the respective periods. During the six months ended June 28, 2025 and June 29, 2024, the Company

recognized revenue of $17 million and $19 million, respectively, that was included in the deferred contract liability

balances at the beginning of the respective periods.

Revenue from goods and services transferred to customers at a point in time accounted for approximately 98% of

revenues for both the three and six months ended June 28, 2025 and June 29, 2024.


10 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

Net sales were as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Retail stores	$287,974	$358,584	$632,415	$773,339
Online, phone, chat and other	39,951	49,829	88,771	105,523
Total Company	$327,925	$408,413	$721,186	$878,862

Obligation for Sales Returns

The activity in the sales returns liability account was as follows (in thousands):


	Six Months Ended
	June 28, 2025	June 29, 2024
Balance at beginning of year	$19,092	$22,402
Additions that reduce net sales	36,098	46,664
Deductions from reserves	(39,540)	(48,535)
Balance at end of period	$15,650	$20,531

9. Stock-Based Compensation Expense

Total stock-based compensation expense was as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Stock awards (1)	$1,064	$3,294	$1,503	$6,438
Stock options	485	698	3,997	1,671
Total stock-based compensation expense (1)	$1,549	$3,992	$5,500	$8,109

___________________________

(1) Changes in stock-based compensation expense include the cumulative impact of the change in the expected achievements of certain performance

targets.

10. Profit Sharing and 401(k) Plan

Under the Company’s profit sharing and 401(k) plan, eligible employees may defer up to 50% of their compensation on a

pre-tax basis, subject to Internal Revenue Service limitations. Each pay period, the Company makes a contribution equal

to a percentage of the employee’s contribution. During the three months ended June 28, 2025 and June 29, 2024, the

Company’s contributions, net of forfeitures, were $1.7 million and $1.2 million, respectively and during the six months

ended June 28, 2025 and June 29, 2024, were $3.5 million and $3.2 million, respectively.


11 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

11. Net Loss per Common Share

The components of basic and diluted net loss per share were as follows (in thousands, except per share amounts):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Net loss	$(25,012)	$(5,051)	$(33,658)	$(12,533)
Reconciliation of weighted-average shares outstanding:
Basic weighted-average shares outstanding	22,903	22,614	22,804	22,560
Dilutive effect of stock-based awards	—	—	—	—
Diluted weighted-average shares outstanding	22,903	22,614	22,804	22,560
Net loss per share – basic	$(1.09)	$(0.22)	$(1.48)	$(0.56)
Net loss per share – diluted	$(1.09)	$(0.22)	$(1.48)	$(0.56)

For the three and six month periods ended June 28, 2025 and June 29, 2024, otherwise dilutive stock-based awards

have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have

had an anti-dilutive effect on our net loss per diluted share. Additional potential dilutive stock-based awards totaling

1.6 million and 1.3 million for the three months ended June 28, 2025 and June 29, 2024, respectively, and 1.8 million

and 1.3 million for the six months ended June 28, 2025 and June 29, 2024, respectively, have been excluded from the

diluted net loss per share calculations because these stock-based awards were anti-dilutive.

12. Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $33.8 million of restructuring costs through December 28, 2024. The Company

has incurred an additional $8.4 million and of restructuring costs during the six months ended June 28, 2025. Charges

incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,

professional fees and other, and asset impairment charges and are included in the restructuring costs line in the

Company’s condensed consolidated statement of operations. The Company expects approximately $8 million of

additional restructuring costs to be incurred through the remainder of 2025, primarily due to severance and employee-

related benefits, contract termination costs, and asset impairment charges.

The following table provides a summary of the Company’s restructuring costs during the three and six months ended

June 28, 2025 and June 29, 2024 (in thousands):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Cash restructuring costs:
Contract termination costs (1)	$1,409	$(230)	$1,295	$4,183
Severance and employee-related benefits	6,335	401	6,492	1,242
Professional fees and other	—	1,648	17	4,494
Total cash restructuring costs	7,744	1,819	7,804	9,919
Non-cash restructuring costs:
Asset impairments (2)	588	—	588	2,500
Total restructuring costs	$8,332	$1,819	$8,392	$12,419

____________________

(1) Primarily comprised of lease termination costs and includes changes in estimate.

(2) Primarily comprised of impairments of property and equipment.


12 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

The following table provides the activity in the Company’s restructuring related liabilities, which are included within

accounts payable, compensation and benefits and other current liabilities on the condensed consolidated balance sheet

(in thousands):


	June 28, 2025	December 28, 2024
Balance at the beginning of year	$3,341	$8,720
Expenses	7,804	14,888
Cash payments	(7,973)	(20,267)
Balance at the end of the period	$3,172	$3,341

Since the initiation of cost reduction actions in the fourth quarter of 2023, the Company has recognized a cumulative

$42.2 million of restructuring costs, as follows (in thousands):


		Cumulative
		June 28, 2025
Cash restructuring costs:
Contract termination costs (1)		$15,732
Severance and employee-related benefits		14,685
Professional fees and other		5,761
Total cash restructuring costs		36,178
Non-cash restructuring costs:
Asset impairments (2)		6,008
Total restructuring costs		$42,186

____________________

(1)Primarily comprised of lease termination costs.

(2) Includes impairments of both lease right-of-use assets and property and equipment.

13. Income Taxes

Income tax expense was $13.2 million for the three months ended June 28, 2025, compared with income tax benefit of

$1.1 million for the same period one year ago. Income tax expense totaled $12.6 million for six months ended June 28,

2025, compared with income tax benefit of $0.4 million for the same period one year ago.

The Company evaluates its deferred income taxes quarterly to determine if valuation allowances are required. As part of

this evaluation, the Company assess whether valuation allowances should be established for any deferred tax assets that

are not considered more likely than not to be realized, using all available evidence, both positive and negative. This

assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of future

profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,

significant weight is given to evidence that can be objectively verified. During the three months ended June 28, 2025,

the Company recorded a change in valuation allowance of $14 million on the basis of management’s reassessment of

the amount of its deferred tax assets primarily related to interest expense that are more likely than not to not be realized.

This decreased the effective tax rate by 66.5% for the three months ended June 28, 2025. The Company continues to

assess the need for the valuation allowance and will make adjustments when appropriate.


13 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

14. Segments

The Company’s chief operating decision maker (CODM), who is the Chief Executive Officer, assesses company-wide

performance and allocates resources based on consolidated financial information. Consequently, the Company views the

entire organization as one reportable segment and the strategic purpose of all operating activities is to support that one

segment.

The CODM manages the Company’s business activities as a single operating and reportable segment at the

consolidated level. The CODM uses consolidated earnings and losses, as reported on the Company’s condensed

consolidated statement of operations, in evaluating performance of the Company in determining how to allocate

resources of the Company as a whole, including investing in the Company’s product development, sales and marketing

campaigns, and employee compensation. The measure of segment assets that is reviewed by the CODM is reported

within the condensed consolidated balance sheet as consolidated total assets. The CODM also uses consolidated

earnings or losses before interest, taxes, depreciation and amortization (Adjusted EBITDA) as the basis to evaluate the

performance of the Company.

The following is a summary of the significant expense categories and consolidated net loss details provided to the

CODM (in thousands):


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Net Sales	$327,925	$408,413	$721,186	$878,862

Less:
Cost of sales	(134,180)	(166,923)	(286,906)	(361,198)
Marketing expenses	(62,427)	(89,483)	(160,368)	(198,512)
Selling expenses	(84,037)	(92,917)	(175,199)	(192,400)
General and administrative	(29,604)	(39,573)	(68,223)	(78,652)
Research and development	(9,420)	(11,578)	(20,323)	(24,019)
Restructuring costs	(8,332)	(1,819)	(8,392)	(12,419)
Interest expense	(11,734)	(12,270)	(22,815)	(24,569)
Income tax (expense) benefit	(13,203)	1,099	(12,618)	374
Net loss	$(25,012)	$(5,051)	$(33,658)	$(12,533)


14 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

15. Commitments and Contingencies

Warranty Liabilities

The activity in the accrued warranty liabilities account was as follows (in thousands):


	Six Months Ended
	June 28, 2025	June 29, 2024
Balance at beginning of period	$6,947	$8,503
Additions charged to costs and expenses for current-year sales	5,878	7,675
Deductions from reserves	(5,800)	(8,048)
Changes in liability for pre-existing warranties during the current year, including expirations	(983)	(171)
Balance at end of period	$6,042	$7,959

Legal Proceedings

The Company is involved from time to time in various legal proceedings arising in the ordinary course of its business,

including primarily commercial, product liability, employment and intellectual property claims. In accordance with U.S.

GAAP, the Company records a liability in its consolidated financial statements with respect to any of these matters when

it is both probable that a liability has been incurred and the amount of the liability can be reasonably estimated. If a

material loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or

range of loss is disclosed. With respect to currently pending legal proceedings, the Company has not established an

estimated range of reasonably possible material losses either because it believes that it has valid defenses to claims

asserted against it, the proceeding has not advanced to a stage of discovery that would enable it to establish an

estimate, or the potential loss is not material. The Company currently does not expect the outcome of pending legal

proceedings to have a material effect on its consolidated results of operations, financial position or cash flows. Litigation,

however, is inherently unpredictable, and it is possible that the ultimate outcome of one or more claims asserted against

the Company could adversely impact its consolidated results of operations, financial position or cash flows. The

Company expenses legal costs as incurred.

Purported Class Action Complaint

On January 14, 2025, purported customers served a putative class action complaint on behalf of themselves and a

putative class of California consumers against Sleep Number in the United States District Court for the Central District of

California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The Plaintiff seeks

injunctive relief, damages and attorney’s fees. Sleep Number brought a motion to dismiss for failure to state a claim and

a motion to transfer or, alternatively, dismiss based on the first-to-file doctrine (citing the purported class action

complaint filed on September 27, 2024 as described below). On April 8, 2025, the Court granted Sleep Number’s

motion to transfer or, alternatively, dismiss and dismissed the matter in its entirety based on the first-to-file doctrine. The

plaintiffs did not appeal the dismissal.

Purported Class Action Complaint

On September 27, 2024, a purported customer served a putative class action complaint on behalf of themself and a

putative class of California consumers against Sleep Number in the United States District Court for the Eastern District of

California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The plaintiff seeks

injunctive relief, damages and attorney’s fees.


15 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

16. Subsequent Event

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted into law. The OBBBA makes permanent key

elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the

business interest expense limitation. ASC 740, “Income Taxes”, requires the effects of changes in tax rates and laws on

deferred tax balances to be recognized in the period in which the legislation is enacted. Consequently, as of the date of

enactment, and during the third quarter of 2025, the Company will evaluate all deferred tax balances under the newly

enacted tax law and identify any other changes required to its financial statements as a result of the OBBBA. The

Company is currently evaluating the impact of the OBBBA on its consolidated financial statements and related

disclosures.


16 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide

a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of

management on its financial condition, results of operations, liquidity and certain other factors that may affect the

Company’s future results. MD&A is presented in seven sections:

•Forward-Looking Statements and Risk Factors

•Business Overview

•Results of Operations

•Liquidity and Capital Resources

•Non-GAAP Data Reconciliations

•Critical Accounting Policies

Forward-looking Statements and Risk Factors

The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to

future plans, events, financial results or performance. You can identify forward-looking statements by those that

are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”

“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or

the negative of these or similar terms. These statements are subject to certain risks and uncertainties that could

cause actual results to differ materially from the Company’s historical experience and its present expectations or

projections. These risks and uncertainties include, among others:

•Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;

•Interest rates remain elevated, and may further increase and impact the cost of servicing the Company’s

indebtedness;

•Access to alternative financing options may depend on factors beyond the Company’s control or require the

Company to accept unfavorable terms;

•Availability of attractive and cost-effective consumer credit options;

•Ability to achieve cost savings, efficiencies and other benefits from its business restructuring actions and to avoid

adverse effects;

•Effectiveness and efficiency of the Company’s marketing strategy and promotions;

•Ability to execute Sleep Number’s Total Retail distribution strategy;

•Ability to compete effectively;

•Ability to achieve and maintain high levels of product and service quality;

•Ability to improve and expand the product line and execute new product introductions;

•Ability to protect the Company’s technology, trademarks and brand, and the adequacy of its intellectual property

rights;

•Dependence on, and ability to maintain working relationships with key suppliers and third parties, including some

that are the only source of supply or services currently used by the Company;

•Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;

•Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,

labor challenges, foreign currency fluctuations, inflation, climate or other disasters and resulting supply shortages,

and production and delivery delays and disruptions;

•Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages;

•Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,

assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer

service operations;

•Ability to effectively complete potential future acquisitions and business combinations;

•Sleep Number’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and

effective personnel;


17 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

•Ability to comply with existing and changing government regulations and laws, and to commercialize new products

and innovations that meet those existing and changing government regulations and laws;

•Ability to identify and withstand cyber threats that could compromise the security of the Company’s systems or those

of third parties upon which it relies and could result in a data breach or business disruption;

•Risks associated with advancements in or adoption of artificial intelligence technologies;

•Adequacy of the Company’s and third-party information systems, and costs and disruptions related to upgrading or

maintaining these systems;

•Volatility of Sleep Number stock, its removal from various stock indices and the potential negative effects of

shareholder activism or of changes in coverage by securities analysts;

•Unfavorable tax treatment;

•Environmental, social and governance risks, including increasing scrutiny and evolving regulatory and stakeholder

expectations; and

•Ability to adapt to climate change and readiness for legal or regulatory responses thereto.

Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk

Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent

Quarterly Reports on Form 10-Q.

The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this

Quarterly Report on Form 10-Q.

Business Overview

Sleep Number is a wellness company and market leader in the design, manufacturing, marketing and distribution of

highly innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of society through

higher quality sleep; to date, it has improved the lives of nearly 16 million people. Sleep Number’s Smart Sleepers

benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and emotional

benefits of life-changing sleep.

Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating

unparalleled physical comfort with a highly advanced sleep wellness platform. The smart beds offer the Company’s

signature firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep

needs of each individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep

the sleeper comfortable throughout the night. Active temperature balancing technology supports the ideal climate for

each sleeper and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with

personalized sleep insights delivered daily, new features regularly added to all smart beds through over-the-air updates

and prices to meet most budgets. Sleep Number® smart beds provide unmatched features, benefits and comfort that

can lead to improved sleep health and wellness for both sleepers.

The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized, digital

sleep wellness platform, a network of millions of highly engaged Smart Sleepers who are loyal brand advocates, a

vertically integrated operating model and a culture of individuality, with an ambitious vision to become one of the

world’s most beloved brands.

The Company’s 3,400 mission-driven team members are dedicated to the Company’s mission of improving lives by

individualizing sleep experiences. They passionately innovate to drive value creation, including our exclusive direct-to-

consumer selling in 630 stores and online, which meets customers whenever and wherever they choose to provide an

exceptional experience and a lifelong relationship. Additionally, the Company partners with world-leading institutions to

bring the power of 34 billion hours of longitudinal sleep data to sleep science and research.

The bedding industry has been in a sector level recession for three years with mattress industry unit volumes returning to

an estimated 24 million units in 2024, the lowest level since 2015. Consumer sentiment remains well below historical

averages, and high interest rates are putting ongoing pressure on the housing market. Consumers continue to scrutinize

spending, with inflation and other factors weighing on their purchasing power. Since initiating the Company’s operating

model transformation in the fourth quarter of 2023, the Company has executed structural changes to reduce fixed

expenses, while prioritizing improving margins and generating cash to create greater financial resilience across market

cycles.


18 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted into law. The OBBBA makes permanent key

elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the

business interest expense limitation. The Company is currently evaluating the impact of the OBBBA on its consolidated

financial statements and related disclosures.

Results of Operations

Quarterly and Year-to-Date Results

Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including

increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return

rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/

closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new

product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity

costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,

consumer sentiment and general economic conditions. The extent to which these external factors will impact the

Company’s business and its consolidated financial results will depend on future developments, which are highly

uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that

may be achieved for any future period.

Highlights

Financial highlights for the three months ended June 28, 2025 were as follows:

•Net sales for the three months ended June 28, 2025 of $328 million decreased 20% from $408 million for the same

period one year ago driven by lower volume and reduced store count.

•The net sales change resulted from a 19% Total Retail comparable sales decrease. For additional details, see the

components of total net sales change on page 20.

•Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a

trailing twelve-month basis for the period ended June 28, 2025 totaled $2.4 million, compared with $2.7 million for

the same period one year ago.

•Operating loss for the three months ended June 28, 2025 was $0.1 million, compared with operating income of

$6.1 million for the same period one year ago. The $6 million decrease in operating income was driven by the lower

net sales and an increase in restructuring expenses of $7 million; partially offset by a $42 million reduction in

operating expenses.

•Adjusted EBITDA for the three months ended June 28, 2025 was $24 million, compared to $28 million for the same

period one year ago. The decrease was primarily due a higher level of net loss.

•Gross profit rate of 59.1% for both the three months ended June 28, 2025 and June 29, 2024. See the gross profit

discussion on page 21 for additional details.

•The $42 million year-over-year reduction in the Company’s operating expenses was due to lower sales and

marketing expenses, general and administrative expenses, and research and development expenses, partially offset

by higher restructuring costs.

•Net loss for the three months ended June 28, 2025 was $25 million, compared with $5 million for the same period

one year ago. Net loss per diluted share was $1.09, compared with $0.22 for the same period one year ago.

•The Company’s adjusted return on invested capital (Adjusted ROIC) was 8.4% on a trailing twelve-month basis for

the period ended June 28, 2025, compared with 3.7% for the comparable period one year ago.

•The Company provided $1 million in cash from operating activities for the six months ended June 28, 2025,

compared with $24 million for the same period one year ago.

•Free cash flow used $7 million for the six months ended June 28, 2025, compared with providing $9 million for the

same period one year ago.

•As of June 28, 2025, the Company had $564 million of borrowings under its revolving credit facility.


19 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.

Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.


	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net sales	$327.9	100.0%	$408.4	100.0%	$721.2	100.0%	$878.9	100.0%
Cost of sales	134.2	40.9%	166.9	40.9%	286.9	39.8%	361.2	41.1%
Gross profit	193.7	59.1%	241.5	59.1%	434.3	60.2%	517.7	58.9%
Operating expenses:
Sales and marketing	146.5	44.7%	182.4	44.7%	335.6	46.5%	390.9	44.5%
General and administrative	29.6	9.0%	39.6	9.7%	68.2	9.5%	78.7	8.9%
Research and development	9.4	2.9%	11.6	2.8%	20.3	2.8%	24.0	2.7%
Restructuring costs	8.3	2.5%	1.8	0.4%	8.4	1.2%	12.4	1.4%
Total operating expenses	193.8	59.1%	235.4	57.6%	432.5	60.0%	506.0	57.6%
Operating (loss) income	(0.1)	—%	6.1	1.5%	1.8	0.2%	11.7	1.3%
Interest expense, net	11.7	3.6%	12.3	3.0%	22.8	3.2%	24.6	2.8%
Loss before income taxes	(11.8)	(3.6%)	(6.2)	(1.5%)	(21.0)	(2.9%)	(12.9)	(1.5%)
Income tax expense (benefit)	13.2	4.0%	(1.1)	(0.3%)	12.6	1.7%	(0.4)	0.0%
Net loss	$(25.0)	(7.6%)	$(5.1)	(1.2%)	$(33.7)	(4.7%)	$(12.5)	(1.4%)

Net loss per share:
Basic	$(1.09)		$(0.22)		$(1.48)		$(0.56)
Diluted	$(1.09)		$(0.22)		$(1.48)		$(0.56)

Weighted-average number of common shares:
Basic	22.9		22.6		22.8		22.6
Diluted	22.9		22.6		22.8		22.6

The percentage of total net sales, by dollar volume, was as follows:


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Retail stores	87.8%	87.8%	87.7%	88.0%
Online, phone, chat and other	12.2%	12.2%	12.3%	12.0%
Total Company	100.0%	100.0%	100.0%	100.0%


20 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

The components of total net sales change, including comparable net sales changes, were as follows:


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Sales change rates:
Retail comparable-store sales (1)	(18%)	(11%)	(17%)	(10%)
Online, phone and chat	(19%)	(13%)	(16%)	(16%)
Total Retail comparable sales change (1)	(19%)	(11%)	(17%)	(11%)
Net opened/closed stores and other	(1%)	0%	(1%)	0%
Total Company	(20%)	(11%)	(18%)	(11%)

___________________________

(1)Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned

within the same shopping center remain in the comparable-store base.

Other sales metrics were as follows:


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Average sales per store (1) (in thousands)	$2,395	$2,732
Average sales per square foot (1)	$775	$883
Stores > $2 million in net sales (2)	47%	62%
Stores > $3 million in net sales (2)	13%	21%
Average revenue per smart bed unit – Total Retail (3)	$5,880	$5,802	$5,940	$5,782

___________________________

(1)Trailing-twelve months Total Retail comparable sales per store open at least one year.

(2)Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).

(3)Represents Total Retail net sales divided by Total Retail smart bed units.

The number of retail stores operating was as follows:


	Three Months Ended		Six Months Ended
	June 28, 2025	June 29, 2024	June 28, 2025	June 29, 2024
Beginning of period	637	661	640	672
Opened	1	4	3	10
Closed	(8)	(19)	(13)	(36)
End of period	630	646	630	646


21 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

Comparison of Three Months Ended June 28, 2025 with Three Months Ended June 29, 2024

Net sales

Net sales for the three months ended June 28, 2025 of $328 million decreased 20% from $408 million for the same

period one year ago driven by lower volume and reduced store count. The net sales change consisted primarily of a 19%

Total Retail comparable sales decrease.

The $80 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$64 million decrease in Retail comparable net sales; (ii) a $9 million decrease from online, phone and chat; and (iii) a $7

million decrease from net store closings and other. Total Retail smart bed unit sales decreased 20% compared with the

prior year. Total Retail average revenue per smart bed unit increased by 1% to $5,880, compared with $5,802 in the

prior-year period.

Gross profit

Gross profit of $194 million for the three months ended June 28, 2025 decreased by $48 million, or 20%, compared with

$241 million for the same period one year ago. The gross profit rate totaled 59.1% of net sales for both the three months

ended June 28, 2025 and June 29, 2024.

The current-year gross profit rate was consistent with the prior-year period and was affected by the following items: (i)

year-over-year product cost reductions through value engineering and ongoing supplier negotiations, increased the rate

by 1.4 ppt; offset by (ii) an unfavorable product mix which deleveraged the rate by 1.1 ppt; and (iii) warranty expenses

along with return and exchange costs which deleveraged the rate by 0.3 ppt.

Sales and marketing expenses

Sales and marketing expenses for the three months ended June 28, 2025 were $146 million, or 44.7% of net sales,

compared with $182 million, or 44.7% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate was consistent with the same period one year ago primarily due to the deleveraging impact of

an 20% net sales decline, partially offset by a 20% decrease in sales and marketing expenses including a 32% lower

media spend.

General and administrative expenses

General and administrative (G&A) expenses totaled $30 million, or 9.0% of net sales, for the three months ended

June 28, 2025, compared with $40 million, or 9.7% of net sales, in the prior-year period. The changes in G&A expenses

consisted mainly of: (i) a $6.1 million year-over-year decrease in company-wide, performance-based incentive

compensation and (ii) a $1.7 million decrease in employee compensation; (iii) a $1.1 million decrease in depreciation and

amortization; and (iv) a $1.0 million decrease in professional and consulting fees. The G&A expenses rate decreased by

0.7 ppt. in the current-year period, compared with the same period one year ago due to the items discussed above

offset by the deleveraging impact of lower net sales.

Research and development expenses

Research and development (R&D) expenses totaled $9 million for the three months ended June 28, 2025, compared

with $12 million with the same period one year ago. The changes in R&D expenses were primarily due to lower

headcount and outside services. Moving forward, the Company’s innovation agenda will focus on maintaining and

improving the Company’s core technologies and introducing additional advancements, while driving costs out of the

product.

Interest expense, net

Interest expense, net totaled $12 million for both the three months ended June 28, 2025, and June 29, 2024.

The increase in the average debt outstanding compared to the same period one year ago was offset by a lower

weighted-average interest rate.


22 \| 2Q 2025 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

Restructuring Costs

Restructuring costs for the three months ended June 28, 2025 were $8 million , compared with $2 million for the same

period one year ago. Charges incurred related to this initiative were comprised of contract termination costs, severance

and employee-related benefits, professional fees and other, and asset impairment charges and are included in the

restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an

additional $8 million of restructuring costs to be incurred through the remainder of 2025, primarily due to severance and

employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,

of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this

Quarterly Report on Form 10-Q for further information on restructuring costs.

Income tax expense (benefit)

Income tax expense was $13.2 million for the three months ended June 28, 2025, compared with income tax benefit of

$1.1 million for the same period one year ago.